Molgramostim Inhalation Solution

Name: Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: B-cell depletion with rituximab
Published: 2026-09-14T15:39:06-04:00

Autoimmune pulmonary alveolar proteinosis

Manufacturer: Savara
Regulatory submission: BLA resubmitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

B-cell depletion with rituximab

1 evidence topic · 3 sources

Options for refractory disease

“Rituximab, plasmapheresis, and lung transplantation are options for refractory disease.” (opens the source at this quote in a new tab)